Evidence map›Paper›PMID 39119826›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2024

Primary aldosteronism with postoperative elevation of aldosterone treated effectively by finerenone: A case report.

Cai-Guo Yu, Bin Cao, Hao-Lin Gong, Jing Ke, Shao-Zhong Xian, Nan-Nan Wu, Dong Zhao

Abstract readCase Reports
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cai-Guo YuCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Bin CaoCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Hao-Lin GongCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Jing KeCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Shao-Zhong XianDepartment of Urology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Nan-Nan WuCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Dong ZhaoCenter for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-9847-5439

Funding

Capital's Funds for Health Improvement and Research 2022-2-7085
6 · The paper itself

Abstract

The authors report a case of primary aldosteronism (PA) with postoperative elevation of aldosterone treated effectively by finerenone. The patient was a hypertensive man with a 30-year history of hypertension and sustained an acute myocardial infarction 5 years ago. Bilateral adrenal nodules with hyperplasia were detected and PA was confirmed. His blood potassium, direct renin concentration, and aldosterone level returned to normal after surgery of right adrenalectomy. However, 1 year after surgery, he experienced a decrease in blood potassium and an increase in aldosterone. A saline infusion test revealed an aldosterone level of 124.47 pg/mL. The patient consented to treatment with finerenone. His aldosterone and potassium levels and blood pressure have been controlled well during follow-up. This case highlights the need to screen for secondary hypertension as early as possible. Finerenone may be effective for patients with PA who are not candidates for surgery and those not relieved after surgery.

Indexed as

AdrenalectomyAldosteroneHyperaldosteronismHypertensionMineralocorticoid Receptor AntagonistsNaphthyridinesHumansMaleMiddle AgedPotassiumTreatment OutcomeAldosteronefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesPotassiumantihypertensive therapyfinerenoneprimary aldosteronismresistant hypertension

Identifiers

PMID39119826
PMCPMC11488330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.